SEC EDGARSEP 11 min read$ORKA

Klein Lawrence Otto sold $6.9M of ORKA

Klein Lawrence Otto (Chief Executive Officer) sold 75,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $91.83 ($90.79–$92.44, $6.89M total) across 3 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Klein Lawrence Otto

Published Sep 1, 2026, 10:35 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 1, 2026, 11:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ORKA

Bearish

medium confidence

Mentioned

$ORKA

Relevance

5/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ORKABearishLow

Why it matters

The CEO's sale of $6.9M could be interpreted as a lack of confidence, but the pre‑arranged 10b5‑1 plan suggests it may be routine.

Market read

Primary insider sale filing; modest materiality for a micro‑cap biotech.

What to watch

Sale may be for personal liquidity, not necessarily negative outlook.

Relevance 5/10Novelty 7/10Timing: 2026-09-01 filing

Background

Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ORKABearishMedium confidence

Context

CEO Klein Lawrence Otto sold 75,000 shares for $6.9M via a 10b5-1 plan on 2026-09-01.

Expected impact

Potential modest downside pressure in near-term trading.

Evidence & confidence

CEO sale of $6.9M is material for a micro‑cap biotech; market may react negatively.

Market effects

Sector

May raise concerns for biotech sector insiders.

Regional

Limited to US biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider sale could be routine pre‑planned 10b5‑1, not a red flag.

Key entities

Person
Klein Lawrence Otto
Chief Executive Officer of Oruka Therapeutics
Company
Oruka Therapeutics, Inc.
Biotech firm listed on NASDAQ under ORKA

Read at source ← All news

AUG 11

$ORKAMed

Oruka Q2 Net Loss Expands; Expects Phase 2 EVERLAST-A 28 Week Data Of ORKA-001 At The End Of Q3 2026

Oruka Therapeutics (ORKA) reported Q2 2026 net loss of $41.21 million, up from $24.57 million a year earlier. The company said it had $1.1 billion in cash, cash equivalents and marketable securities as of June 30, 2026. Phase 2 EVERLAST-A 28-week data for ORKA-001 is expected end of Q3 2026, with 52-week data in Dec 2026.

rttnews.com3 min

AUG 10

$ORKAMedAI 8/10

Oruka Therapeutics reports Q2 2026 results: $1.1B cash; net loss $41.2M in quarter

Oruka Therapeutics reported Q2 2026 cash, cash equivalents and marketable securities of $1.1B as of June 30, 2026, and a net loss of $41.2M. R&D was $43.3M and G&A $6.9M, with $8.9M interest income. The company cited clinical updates for ORKA-001 and ORKA-002 and said funding should support a BLA filing for ORKA-001.

tradingview.com1 min

AUG 10

$ORKAMed

Oruka Therapeutics, Inc. (ORKA): Results of Operations and Financial Condition

Oruka Therapeutics, Inc. (ORKA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Oruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update EVERLAST-A Week 28 data expected at the end of 3Q 2026; 52-week data for all participants expected in December 2026 EVERLAST-B fully enrolled ahead of schedule, with Week 1

SEC EDGAR 8-K6 min

JUL 2

$ABBVMed

Biotech Gives SBIO Its Best Month Since 2023

In June, the ALPS Medical Breakthroughs ETF (SBIO) returned 18.7%, its best month since Dec 2023, according to VettaFi. Apogee Therapeutics (APGE) added 2.18 pts after AbbVie (ABBV) agreed to acquire it for about $10.9B ($135.11/share). Definium (DFTX) added 1.58 pts after a Phase 3 MDD readout; other movers included Oruka (ORKA).

etftrends.com4 min

JUL 2

$ORKALowAI 9/10

Fairmount Funds Management LLC sold $300.0M of ORKA (indirect holdings)

Fairmount Funds Management LLC sold 3,553,410 indirectly-held shares of Oruka Therapeutics, Inc. (ORKA) at $84.43 ($300.01M total) on 2026-07-01.

SEC EDGAR1 min

MAY 31

$ORKALow

An Oruka Therapeutics (ORKA) Insider Sold 105,000 Shares Worth $6.2 Million

According to an SEC Form 4 filed May 21, 2026, Oruka Therapeutics director Carl Dambkowski sold 105,000 shares of common stock for about $6.19 million at a weighted average price of $58.97. After the sale, he held 73,743 shares (~$4.33 million). The shares came from exercising 62,260 vested options.

finance.yahoo.com4 min